62 results about "Benign prostatic hyperplasia (BPH)" patented technology

This invention relates to a non-invasive predictive kit and method for the progression of benign prostatic hyperplasia (BPH) based on prostatic fluid. The invention provides the application of FGF9 as a non-invasive predictive biomarker for the progression of BPH based on prostatic fluid, wherein the concentration of FGF9 in prostatic fluid serves as an indicator of BPH progression. The invention also provides a method for detecting the concentration of FGF9 in prostatic fluid for non-disease diagnostic purposes. Compared with existing technologies, the non-invasive BPH detection method based on prostatic fluid of this invention has advantages such as non-invasiveness, accuracy, simplicity, practicality, and scalability, and is expected to be widely used in the clinical diagnosis and treatment of prostate diseases.

The invention belongs to the technical field of traditional Chinese medicine, and relates to a pine pollen compound fermentation composition and a preparation method and application thereof, and the preparation method comprises the following steps: (1) water extraction; (2) enzymolysis; (3) sterilizing; (4) fermenting; (5) sterilizing; and (6) drying to obtain the pine pollen compound fermentation composition. The pine pollen compound fermentation composition disclosed by the invention can promote rapid dissolution of key active ingredients and enrich the content of active ingredients, namely flavone and polysaccharide, for improving benign prostatic hyperplasia in the raw materials, so that a foundation is laid for the benign prostatic hyperplasia improvement effect of a compound fermentation product; the inherent bitter taste of the pine pollen and other raw materials is effectively reduced, and the palatability of the product and the pleasure of consumers are improved; animal experiments prove that the traditional Chinese medicine composition has the beneficial effect of improving benign prostatic hyperplasia.

Computer-implemented methods for providing interactive electronic treatment assistance for benign prostatic hyperplasia and advanced prostate cancer are disclosed. The methods can include automatically sending, by a disease and disorder treatment device, an electronic pathway sign-up link to a smart mobile device. The method can include sending a plurality of inquiries about the BPH condition and / or the advanced prostate cancer condition, to the smart mobile device. The method can include receiving a plurality of patient responses from the smart mobile device. The method can include processing and storing the plurality of patient responses. The method can include providing, by the disease and disorder treatment device, patient education about various treatment therapies for advanced prostate cancer. The method can include automatically monitoring a patient having the advanced prostate cancer condition during the various treatment therapies. The method can include intervening with the various treatment therapies using the smart mobile device.

The invention relates to the technical field of biology, in particular to application of a prostate intermediate state cell and an inhibitor of the prostate intermediate state cell, and discloses application of the prostate intermediate state cell and an organ or tissue comprising the prostate intermediate state cell as a target in screening of drugs for treating prostatitis or prostatic hyperplasia. The prostate intermediate state cell inhibitor is applied to preparation of a medicine for treating prostatitis or benign prostatic hyperplasia; the inhibitor of the prostate intermediate state cells comprises one or more of a GRN signal channel inhibitor and a Sema4 signal channel agonist. The application provides a new therapeutic target for treatment of prostatitis or benign prostatic hyperplasia and drug screening, and provides a potential strategy for clinical treatment of prostatitis and benign prostatic hyperplasia.

This invention discloses the application of two dipeptides in the preparation of a diagnostic kit for differentiating prostate cancer from benign prostatic hyperplasia (BPH). The invention reveals that the combination of the dipeptides H-Asp-Phe-OH (DF) and H-Leu-Ala-OH (LA) with prostate-specific antigen (PSA) has high diagnostic value in differentiating prostate cancer from BPH, with a high accuracy rate. The combined diagnostic effect of these three peptides is significantly better than that of PSA alone in differentiating between prostate cancer and BPH, showing promise for development into a diagnostic kit for differentiating prostate cancer from BPH.

Devices and systems are disclosed for managing and / or treating body tissues obstructing a hollow body lumen, including the prostatic lobe tissues obstructing the urethra, for example conditions including benign prostatic hyperplasia (BPH), bladder outlet obstruction (BOO), benign prostatic obstruction (BPO) and associated lower urinary tract symptoms (LUTS). An implant is maintained in a constrained configuration within a distal portion of an elongated sheath so that is may be deployed by driving the implant with a pusher coaxially disposed within the sheath. An implant engaging element helps maintain control of the implant during deployment.

The invention provides methods for isolating RNA from whole urine and urine fractions for the diagnosis of prostate cancer and / or benign prostate hyperplasia. An exemplary method for diagnosing prostate cancer in an individual, said method comprises: (a) determining the amount of RNA encoding one or more diagnostic genes in the soluble urine fraction of a urine sample obtained from said individual; (b) comparing the amount of said RNA to a reference value for said one or more diagnostic genes, wherein said reference value is derived from the amount of RNA encoding said one or more diagnostic genes in one or more individuals that do not have prostate cancer; and (c) diagnosing said individual as having prostate cancer when the amount of said RNA is greater than said reference value.

The application discloses application of CFHR5 protein in preparation of a kit for diagnosing and distinguishing prostate cancer and benign prostatic hyperplasia. It is found by the application that the CFHR5 protein has high diagnostic value for distinguishing prostate cancer and benign prostatic hyperplasia, the accuracy of diagnosis and distinction is high, and the CFHR5 protein has the prospect of being developed into a kit for diagnosing and distinguishing prostate cancer and benign prostatic hyperplasia.

The invention provides a bisphenol A induced rat benign prostatic hyperplasia model and a construction method, and relates to the technical field of animal models. The method comprises the following steps: S1, selecting rats which are 8-9 months old and 9-10 weeks old, and adaptively feeding the rats in a suitable environment for 7 days or more; s2, jointly applying high-fat feed and bisphenol A to the adaptively fed rats to induce benign prostatic hyperplasia; the induction time is 60-80 days, and performing biological index evaluation after the induction is completed. The exposure level of low-dose BPA adopted by the invention is closer to the actual environment exposure level of people, and a main exposure way is simulated through oral gavage. The model constructed by the method can better simulate the real process of chronic and low-dose exposure pathopoiesis of the environmental endocrine disrupter in etiology, and provides an experimental tool with more practical significance for related risk evaluation.

1. The name of the design product: hot steam treatment equipment. 2. The use of the design product: used with the prostate hot steam treatment instrument to relieve symptoms and obstruction related to benign prostatic hyperplasia (BPH). 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1.

The invention relates to a compound as shown in a formula (I) or a salt or a solvate thereof, and also relates to a preparation method of the compound as shown in the formula (I), a pharmaceutical composition containing the compound as shown in the formula (I), and application of the compound as shown in the formula (I) or the pharmaceutical composition containing the compound as shown in the formula (I) in preparation of medicines for treating alopecia and benign prostatic hyperplasia. Through injection administration, the administration effect can be maintained for a long time, and the long-acting pharmaceutical property is ideal.

The invention provides an application of an aromatase gene CYP19A1 methylation level in evaluation of benign prostatic hyperplasia progress degree. The traditional Chinese medicine composition is used for treating benign prostatic hyperplasia patients from early progression; whether methylation and demethylation occur in CpG islands in promoter regions of aromatase genes CYP19A1 in prostate tissues of bladder cancer patients and elderly benign prostatic hyperplasia patients who are age-matched and subjected to radical bladder resection and prostatic resection are detected and analyzed, and whether methylation and demethylation occur in the CpG islands in the promoter regions of the aromatase genes CYP19A1 in the prostate tissues or not is judged; according to the present invention, the CYP19A1 gene methylation level is low and the CYP19A1 gene demethylation level is high in the prostate tissue of the early stage progression BPH patient, and the aromatase expression of the coding protein of the CYP19A1 gene is up-regulated, such that the aromatase gene CYP19A1 methylation change is related to the benign prostatic hyperplasia progress, and the new thought is provided for the risk stratification of the benign prostatic hyperplasia disease;

The present invention relates to compounds that are activators of the Alpha1A-Adrenergic Receptor (α1A-AR) and methods of using such compounds: for treating neurological conditions, for cardio-protection, and for treating other conditions. In certain embodiments, the α1A-AR activator compound is a compound of Formula I. In certain embodiments, the neurological condition is Alzheimer's disease, benign prostatic hyperplasia, memory loss, depression, or Parkinson's disease.

The present invention relates to a composition, a kit, and an information providing method for diagnosing prostate cancer using the methylation level of CpG regions. By using the composition, the kit, and the information providing method according to the present invention, it is possible to distinguish between prostate cancer and benign prostatic hyperplasia, and thereby diagnose prostate cancer not only quickly and accurately, but also early.

The dilatation balloon device comprises a catheter, a first balloon body, a protruding structure and a connecting piece, the catheter extends in the front-back direction, a first channel penetrating in the front-back direction is formed in the catheter, the first balloon body is arranged at the front end of the catheter, the front end of the first channel is communicated with the interior of the first balloon body, and the rear end of the first channel is communicated with a pressurizing device. The protruding structures are arranged on the outer surface of the first bag body in a protruding mode and distributed in a long shape extending in the front-back direction, in a projection view perpendicular to the front-back direction, the protruding structures are distributed on the periphery of the first bag body in a non-centrosymmetric mode, and the connecting piece is arranged at the rear end of the catheter and used for communicating the first channel with the pressurizing device. In the invention, the bulge structure can apply pressure to the affected part in a targeted manner, so that the affected part is cracked before other tissues in the bulge process of the first capsule body, and the treatment purpose is achieved. Therefore, the treatment accuracy can be improved, unnecessary tearing of healthy tissues is reduced, the complication risk is reduced, and the minimally invasive treatment requirements of diseases such as benign prostatic hyperplasia are met.

The invention provides application of TRMT61A as a target spot in preparation of a medicine for preventing or treating benign prostatic hyperplasia. The TRMT61A is specifically targeted through shRNA, pathogenic signals are blocked from the post-transcriptional level, accurate intervention on benign prostatic hyperplasia is achieved, dependence on androgen pathways is completely avoided, unavoidable sexual dysfunction and other serious side effects of traditional drugs are fundamentally avoided, and the life quality of patients is remarkably improved.

In some aspects thereof, the present invention discloses compositions and methods for treating premature ejaculation utilizing tamsulosin at a 0.2 milligram dose administered orally or transdermally every 48 hours. Tamsulosin functions as a selective antagonist of alpha-1a and 1b adrenergic as well as 5HT1A serotonergic receptors implicated in seminal emission pathways. The quantity and frequency of dosing provides an optimal degree of reversible receptor blockade to mildly inhibit sympathetic and serotonergic mediated smooth muscle contraction kinetics governing seminal fluid secretion and transport. This marginally suppresses rate of emission to prolong intercourse without profoundly arresting physiological processes underlying ejaculation.

The invention provides a preparation method of the diterpenoid composition. The method comprises the following steps: extracting a rubus chingii material to obtain an extract composition; suspending the extract composition, and performing liquid-liquid extraction on the suspension to obtain a target extraction part; adsorbing and separating the target extraction part through macroporous resin, and eluting to obtain a target fraction; eluting the target fraction to obtain a target eluate; and drying the target eluate to obtain a powder product. Also provided are a diterpenoid composition obtained by the method, an oral composition comprising the diterpenoid composition, a composition comprising at least one diterpenoid extract of rubus chingii, the use of the composition in the preparation of a medicament for the treatment of benign prostatic hyperplasia (BPH) in a subject, and a method of treating BPH in a subject.

1. The name of the design product: disposable surgical instruments for treating benign prostatic hyperplasia. 2. The use of the design product: medical instruments for minimally invasive treatment of benign prostatic hyperplasia by condensing steam. 3. The design features of the design product: in shape. 4. The picture or photo that best indicates the design features: perspective view.

This invention discloses an edible fungus extract, its preparation method, and its application in the preparation of products that enhance immunity and lower lipids. The edible fungus extract is composed of Ganoderma lucidum water extract and enoki mushroom water extract. The research of this invention shows that the mixture of Ganoderma lucidum water extract and enoki mushroom water extract has the effect of synergistically enhancing immune regulation and lowering lipids, and can be added as a functional food ingredient, providing a basis for the research and development of high-value-added edible fungus products.

An embodiment relates to a sustained-release injectable composition containing dutasteride, which may exhibit a sustained dutasteride release effect for 3 months or more even when the dose of dutasteride is equal to or less than that of existing AVODART®, which is taken once a day, thereby exhibiting a long-acting drug effect by a single injection. In addition, the injectable composition may exhibit a therapeutic effect on benign prostatic hyperplasia, prostate cancer, and hair loss continuously for 3 months or more, may maintain an effective concentration of the drug at a constant level by controlling the release of the drug due to the constant average diameter of the microparticles contained in the sustained-release injectable composition, and may reduce foreign body sensation and pain when administered by injection to a patient.

The invention discloses application of idarubicin in preparation of a medicine for treating benign prostatic hyperplasia, and relates to the technical field of biological medicine. The invention discloses application of idarubicin in preparation of a medicine for treating benign prostatic hyperplasia. The application of idarubicin in BPH treatment is found and confirmed for the first time: (1) the specificity effectiveness of BPH, preferably gland proliferation type BPH, is verified, and the intervention effect of idarubicin on a core target TP63 and gland proliferation is clear; (2) the regulation and control effect on prostate volume and gland hyperplasia is supported through in-vivo experimental data; and (3) curative effect verification at a clinical level is carried out, and a clinical application path of subtype screening-drug intervention-curative effect evaluation is established, so that transformation in BPH precise treatment is facilitated. According to the research, through a complete evidence chain of cell, animal and multi-center clinical retrospective research, the treatment value of idarubicin on BPH, especially gland proliferation type BPH, is verified, and the blank in the field is filled.

The invention relates to a sustained release preparation for treating benign prostatic hyperplasia. The sustained release preparation contains silodosin and a sustained release material, the sustained-release material is a hydrophilic gel skeleton sustained-release material with the viscosity of 1000 mPa.s or above. The sustained-release preparation disclosed by the invention can realize an expected sustained-release effect in vivo.

A stable oral liquid composition of Terazosin and its pharmaceutically acceptable salt which is useful for treating symptomatic benign prostatic hyperplasia (BPH) and hypertension is disclosed. The oral liquid composition includes terazosin or a pharmaceutically acceptable salt thereof, at least one pH modifier, at least one pharmaceutically acceptable excipient, and a liquid vehicle.

This invention discloses a bird's nest composition with preventive and therapeutic effects on benign prostatic hyperplasia (BPH), its preparation method, and its application, belonging to the field of composition technology. The bird's nest composition is prepared from the following parts by weight of bird's nest and traditional Chinese medicine as raw materials: 3-5 parts bird's nest, 0.001-0.024 parts ZnCl2, 2-6 parts peony stamens, 10-30 parts Codonopsis pilosula, 10-30 parts Astragalus membranaceus, 5-15 parts Poria cocos, and 10-30 parts Imperata cylindrica root. The bird's nest composition of this invention has a clear efficacy in preventing and treating BPH. Experiments using a rat BPH model show that the bird's nest composition of this invention can significantly improve the endocrine disorders in the animal model and has a good preventive and therapeutic effect on testosterone propionate-induced BPH.

The invention discloses a siRNA preparation for treating benign prostatic hyperplasia, and belongs to the technical field of biological pharmacy. By analyzing mRNA sequences of human and rat SRD5A2, two siRNA sequences for silencing SRD5A2 protein expression are designed and synthesized. The two kinds of siRNA transfect human normal prostate matrix immortalized cells through lipidosome, and both siRNA-1 and siRNA-2 can achieve a good SRD5A2 gene silencing effect. Two siRNA-liposome compounds are intravenously injected into a benign prostatic hyperplasia model rat induced by testosterone propionate, and the siRNA-1 and the siRNA-2 can effectively silence the expression of the SRD5A2 in the rat body. After a prostatic hyperplasia model rat is treated by the two siRNAs, the content of dihydrotestosterone DHT in serum is remarkably reduced compared with that of an untreated model group, and the prostate index is also remarkably reduced.

This invention discloses the application of the TP63 gene or protein in the preparation of drugs for treating benign prostatic hyperplasia (BPH), belonging to the field of biomedical technology. The application of the TP63 gene or protein in the preparation of drugs for treating BPH involves precise screening of the target TP63 gene or protein based on subtype-specific proteomics data, combined with dual verification of "drugability" and "clinical relevance," enabling its transformation into a clinical drug; and possessing a complete chain of evidence for multi-cell line functional verification, fully demonstrating the effectiveness of the target intervention.

The invention belongs to the technical field of medicines, and particularly relates to application of wild buckwheat rhizome or an extract thereof to prevention or treatment of AR-positive prostatic cancer or treatment of benign prostatic hyperplasia. The invention provides application of fagopyrum dibotrys or an extract thereof in preparation of a medicine or a health care product for preventing or treating AR-positive prostatic cancer or treating benign prostatic hyperplasia. Meanwhile, the invention discloses the wild buckwheat rhizome water extract, a preparation method thereof and a pharmaceutical composition or health care product thereof. Researches show that the wild buckwheat rhizome and the extract thereof can significantly reduce expression of AR and PSA, specifically inhibit proliferation of AR-positive prostate cancer cells and induce death of the AR-positive prostate cancer cells, and inhibit proliferation of benign prostatic hyperplasia related cells at the same time. The rhizoma fagopyri dibotryis and the extract thereof can target prostate tissues with high AR expression, a novel intervention scheme with treatment accuracy and clinical safety is provided for prostate cancer prevention and treatment and benign prostatic hyperplasia management, and the rhizoma fagopyri dibotryis and the extract thereof have important clinical application value.

One aspect relates to a composition, a kit, and a method for detecting or isolating nucleic acids using the same. By using the composition, kit, and method for detecting or isolating nucleic acids according to one aspect, high-concentration and high-purity nucleic acids can be detected or isolated rapidly, simply, and accurately at low cost without electricity and special equipment, such as centrifugation, vacuum pumps, and heat controllers, used in conventional column and bead-based methods. Furthermore, by using the composition according to one aspect to detect or isolate one or more nucleic acids selected from the group consisting of miR-141-3p, miR-375-3P, miR-483-5P, and miR-574-3P, prostate cancer (PCa) in patients with benign prostatic hyperplasia (BPH) can be diagnosed rapidly, precisely, and early, and infectious diseases can be diagnosed rapidly, precisely, and early by detecting or isolating nucleic acids derived from microorganisms that cause infectious diseases.